

Global Dual GLP-1R/GIPR Agonist Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G36D8C099489EN.html>

Date: January 2026

Pages: 101

Price: US\$ 4,480.00 (Single User License)

ID: G36D8C099489EN

Abstracts

The global Dual GLP-1R/GIPR Agonist market size is expected to reach \$ 65873 million by 2032, rising at a market growth of 11.0% CAGR during the forecast period (2026-2032).

In 2025, global Dual GLP-1R/GIPR Agonist production reached approximately 161.44 M Units, with an average global market price of around 190 USD per Unit.

A Dual GLP-1R/GIPR Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity. To date, Tirzepatide is the only commercially available Dual GLP-1R/GIPR Agonist product in the world.

Dual GLP-1R/GIPR Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for

effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma's most strategically important therapeutic area.

The upstream raw materials for Dual GLP-1R/GIPR Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.

The single-line production capacity of Dual GLP-1R/GIPR Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

This report studies the global Dual GLP-1R/GIPR Agonist production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Dual GLP-1R/GIPR Agonist and provides market size (US\$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Dual GLP-1R/GIPR Agonist that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Dual GLP-1R/GIPR Agonist total production and demand, 2021-2032, (K Units)

Global Dual GLP-1R/GIPR Agonist total production value, 2021-2032, (USD Million)

Global Dual GLP-1R/GIPR Agonist production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)

Global Dual GLP-1R/GIPR Agonist consumption by region & country, CAGR, 2021-2032 & (K Units)

U.S. VS China: Dual GLP-1R/GIPR Agonist domestic production, consumption, key domestic manufacturers and share

Global Dual GLP-1R/GIPR Agonist production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)

Global Dual GLP-1R/GIPR Agonist production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)

Global Dual GLP-1R/GIPR Agonist production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)

This report profiles key players in the global Dual GLP-1R/GIPR Agonist market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Roche, Viking Therapeutics, Ascleptis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Dual GLP-1R/GIPR Agonist market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), volume (production, consumption) & (K Units) and average price (US\$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Dual GLP-1R/GIPR Agonist Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Dual GLP-1R/GIPR Agonist Market, Segmentation by Type:

Injection

Oral Administration

Others

Global Dual GLP-1R/GIPR Agonist Market, Segmentation by Receptor Agonist Properties:

Balanced

Biased

Others

Global Dual GLP-1R/GIPR Agonist Market, Segmentation by Medicinal Efficacy:

Long-acting

Short-acting

Global Dual GLP-1R/GIPR Agonist Market, Segmentation by Application:

Diabetes

Obesity

Others

Companies Profiled:

Eli Lilly

Roche

Viking Therapeutics

Asclepis Pharma

Jiangsu Hengrui Medicine

East China Pharmaceutical

Tonghua Dongbao Pharmaceutical

Lepu Medical Technology

Hansoh Pharma

Key Questions Answered:

1. How big is the global Dual GLP-1R/GIPR Agonist market?
2. What is the demand of the global Dual GLP-1R/GIPR Agonist market?
3. What is the year over year growth of the global Dual GLP-1R/GIPR Agonist market?
4. What is the production and production value of the global Dual GLP-1R/GIPR Agonist market?
5. Who are the key producers in the global Dual GLP-1R/GIPR Agonist market?
6. What are the growth factors driving the market demand?

I would like to order

Product name: Global Dual GLP-1R/GIPR Agonist Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G36D8C099489EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G36D8C099489EN.html>